Related references
Note: Only part of the references are listed.The SwissSimilarity 2021 Web Tool: Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience
Maiia E. Bragina et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
Sachiho Miyata et al.
SCIENTIFIC REPORTS (2021)
Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer
Sosmitha Girisa et al.
MOLECULAR BIOMEDICINE (2021)
In-silico therapeutic investigations of arjunic acid and arjungenin as an FXR agonist and validation in 3T3-L1 adipocytes
Mohan T. Manu et al.
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2020)
Bile acid receptors FXR and TGR5 signaling in fatty liver diseases an therapy
John Y. L. Chiang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2020)
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
Donatella Chianelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential
Siyi He et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Obeticholic acid-a new therapy in PBC and NASH
Roger W. Chapman et al.
BRITISH MEDICAL BULLETIN (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Michael K. Badman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement
Yun Ji et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Obeticholic acid in primary biliary cholangitis: where we stand
Vignan Manne et al.
CURRENT OPINION IN GASTROENTEROLOGY (2019)
ADMET modeling approaches in drug discovery
Leonardo L. G. Ferreira et al.
DRUG DISCOVERY TODAY (2019)
The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
S. Di Matteo et al.
PLOS ONE (2019)
The farnesoid X receptor: a potential target for expanding the therapeutic arsenal against kidney disease
Christos Masaoutis et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
Eloy D. Hernandez et al.
HEPATOLOGY COMMUNICATIONS (2019)
Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism
Preeti Pathak et al.
HEPATOLOGY (2018)
Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking
Antonella Giancristofaro et al.
MEDCHEMCOMM (2018)
Molecular Insights into the Interaction of RONS and Thieno[3,2-c]pyran Analogs with SIRT6/COX-2: A Molecular Dynamics Study
Dharmendra K. Yadav et al.
SCIENTIFIC REPORTS (2018)
Activation of Farnesoid X Receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts
Ines Barone et al.
CANCER LETTERS (2018)
Computer-aided Drug Design and Drug Pharmacokinetic Prediction: A Mini-review
Jamshid Tabeshpour et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
James J. Connolly et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2018)
Predict drug permeability to blood-brain-barrier from clinical phenotypes: drug side effects and drug indications
Zhen Gao et al.
BIOINFORMATICS (2017)
Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives
Juan P. Arab et al.
HEPATOLOGY (2017)
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
David C. Tully et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Molecular Dynamics Simulations of Water Confined in Calcite Slit Pores: An NMR Spin Relaxation and Hydrogen Bond Analysis
Sylvia M. Mutisya et al.
JOURNAL OF PHYSICAL CHEMISTRY C (2017)
LigParGen web server: an automatic OPLS-AA parameter generator for organic ligands
Leela S. Dodda et al.
NUCLEIC ACIDS RESEARCH (2017)
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
Antoine Daina et al.
SCIENTIFIC REPORTS (2017)
Farnesoid X receptor, a novel protooncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1
Wenjie You et al.
SCIENTIFIC REPORTS (2017)
Farnesoid X Receptor an Emerging Target to Combat Obesity
C. Daniel De Magalhaes Filho et al.
DIGESTIVE DISEASES (2017)
The application of principal component analysis to drug discovery and biomedical data
Alessandro Giuliani
DRUG DISCOVERY TODAY (2017)
Bile Acids in Physiology, Pathology and Pharmacology
Jose J. G. Marin et al.
CURRENT DRUG METABOLISM (2016)
Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research
Martin Pouliot et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening
Vincent Zoete et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2016)
Activated FXR Inhibits Leptin Signaling and Counteracts Tumor-promoting Activities of Cancer-Associated Fibroblasts in Breast Malignancy
Cinzia Giordano et al.
SCIENTIFIC REPORTS (2016)
Binding energies of tyrosine kinase inhibitors: Error assessment of computational methods for imatinib and nilotinib binding
Clifford W. Fong
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Sungsoon Fang et al.
NATURE MEDICINE (2015)
FXR expression is associated with dysregulated glucose and lipid levels in the offspring kidney induced by maternal obesity
Sarah J. Glastras et al.
NUTRITION & METABOLISM (2015)
In silico ADME/T modelling for rational drug design
Yulan Wang et al.
QUARTERLY REVIEWS OF BIOPHYSICS (2015)
Bile acid nuclear receptor FXR and digestive system diseases
Lili Ding et al.
ACTA PHARMACEUTICA SINICA B (2015)
Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
Guodong Li et al.
ACTA PHARMACEUTICA SINICA B (2015)
Prevention of Spontaneous Hepatocarcinogenesis in Farnesoid X Receptor-Null Mice by Intestinal-Specific Farnesoid X Receptor Reactivation
Chiara Degirolamo et al.
HEPATOLOGY (2015)
Role of farnesoid X receptor in inflammation and resolution
Firdose Begum Shaik et al.
INFLAMMATION RESEARCH (2015)
Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis
Hong Ping Zhang et al.
ALLERGY AND ASTHMA PROCEEDINGS (2014)
A Review of Methods Available to Estimate Solvent-Accessible Surface Areas of Soluble Proteins in the Folded and Unfolded States
Syed Ausaf Ali et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2014)
Knocking on FXR's Door: The Hammerhead-Structure Series of FXR Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities
Christian Gege et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2014)
Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes
Lin Ding et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2014)
Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds
Javier Vaquero et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
Quantification of skin penetration of antioxidants of varying lipophilicity
M. J. Abla et al.
INTERNATIONAL JOURNAL OF COSMETIC SCIENCE (2013)
A Meta-analysis of the Effectiveness of the Opioid Receptor Antagonist Alvimopan in Reducing Hospital Length of Stay and Time to GI Recovery in Patients Enrolled in a Standardized Accelerated Recovery Program After Abdominal Surgery
P. G. Vaughan-Shaw et al.
DISEASES OF THE COLON & RECTUM (2012)
Bridging solubility between drug discovery and development
Li Di et al.
DRUG DISCOVERY TODAY (2012)
The influence of lipophilicity in drug discovery and design
John A. Arnott et al.
EXPERT OPINION ON DRUG DISCOVERY (2012)
FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model
Ulrich Deuschle et al.
PLOS ONE (2012)
Predicting skin permeability of chemical substances using a quantitative structure-activity relationship
Yen-Ching Chang et al.
2012 INTERNATIONAL SYMPOSIUM ON SAFETY SCIENCE AND TECHNOLOGY (2012)
Nuclear bile acid receptor FXR in the hepatic regeneration
Wei-Dong Chen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum
Ulrike Grienke et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Nuclear Receptors in Liver Disease
Martin Wagner et al.
HEPATOLOGY (2011)
Increased Activation of the Wnt/β-Catenin Pathway in Spontaneous Hepatocellular Carcinoma Observed in Farnesoid X Receptor Knockout Mice
Andy Wolfe et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
ADME Evaluation in Drug Discovery. 9. Prediction of Oral Bioavailability in Humans Based on Molecular Properties and Structural Fingerprints
Sheng Tian et al.
MOLECULAR PHARMACEUTICS (2011)
Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease
Raffaella M. Gadaleta et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2010)
Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
Xiaoxin X. Wang et al.
DIABETES (2010)
Improvement of Physiochemical Properties of the Tetrahydroazepinoindole Series of Farnesoid X Receptor (FXR) Agonists: Beneficial Modulation of Lipids in Primates
Joseph T. Lundquist et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
PubChem: a public information system for analyzing bioactivities of small molecules
Yanli Wang et al.
NUCLEIC ACIDS RESEARCH (2009)
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Philippe Lefebvre et al.
PHYSIOLOGICAL REVIEWS (2009)
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria
Xiaoxin X. Wang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
FXR: a metabolic regulator and cell protector
Yan-Dong Wang et al.
CELL RESEARCH (2008)
Strategies to assess blood-brain barrier penetration
Li Di et al.
EXPERT OPINION ON DRUG DISCOVERY (2008)
GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation
Berk Hess et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2008)
Radius of gyration as an indicator of protein structure compactness
M. Yu. Lobanov et al.
MOLECULAR BIOLOGY (2008)
The Role of FXR in Disorders of Bile Acid Homeostasis
Jyrki J. Eloranta et al.
PHYSIOLOGY (2008)
Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation
Stephen M. Soisson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation
Fabrice Journe et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
Insook Kim et al.
JOURNAL OF LIPID RESEARCH (2007)
Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy
Tao Jiang et al.
DIABETES (2007)
Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs:: In vitro/in vivo case studies
Panayiotis P. Constantinides et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
The role of size and charge for blood-brain barrier permeation of drugs and fatty acids
Anna Seelig
JOURNAL OF MOLECULAR NEUROSCIENCE (2007)
The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression
Karen E. Swales et al.
CANCER RESEARCH (2006)
FXR, a multipurpose nuclear receptor
Florence Y. Lee et al.
TRENDS IN BIOCHEMICAL SCIENCES (2006)
GROMACS: Fast, flexible, and free
D Van der Spoel et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
The GROMOS software for biomolecular simulation:: GROMOS05
M Christen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
Does inhibition of P-glycoprotein lead to drug-drug interactions?
D Balayssac et al.
TOXICOLOGY LETTERS (2005)
Blood-brain barrier permeation models: Discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates
M Adenot et al.
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES (2004)
Selection criteria for drug-like compounds
I Muegge
MEDICINAL RESEARCH REVIEWS (2003)
The effect of food components on the absorption of P-gp substrates: a review
S Deferme et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2003)
6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
R Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Convergence of sampling in protein simulations
B Hess
PHYSICAL REVIEW E (2002)
Further development and validation of empirical scoring functions for structure-based binding affinity prediction
RX Wang et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2002)
Prediction of drug absorption using multivariate statistics
WJ Egan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
